Table 4.
Factors associated with overall survival for total cohort.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
| hsCRP (mg/l) | ||||
| >10 vs. ≤ 10 | 2.210 (1.339–3.647) | 0.002 | 2.168 (1.299–3.616) | 0.003 |
|
| ||||
| LDH (U/l) | ||||
| >480 vs. ≤ 480 | 2.335 (1.351–4.036) | 0.002 | 2.213 (1.273–3.845) | 0.005 |
|
| ||||
| CEA (ng/ml) | ||||
| >5 vs. ≤ 5 | 1.842 (1.119–3.033) | 0.016 | ||
|
| ||||
| CA15-3 (U/ml) | ||||
| >30 vs. ≤ 30 | 1.289 (0.673–2.469) | 0.444 | ||
|
| ||||
| Age (years) | ||||
| ≥50 vs. <50 | 0.555 (0.330–0.932) | 0.026 | ||
|
| ||||
| ECOG-PS | ||||
| 1/2 vs. 0 | 2.352 (0.939–5.893) | 0.068 | ||
|
| ||||
| HER2 | ||||
| (−) vs. (+) | 1.009 (0.583–1.747) | 0.973 | ||
|
| ||||
| Hormone receptors (HRs) | ||||
| (−) vs. (+) | 0.681 (0.412–1.124) | 0.133 | ||
|
| ||||
| No. of metastatic sites | ||||
| ≥2 sites vs. 1 site | 1.802 (1.095–2.965) | 0.020 | ||
|
| ||||
| Chemotherapy line | ||||
| ≥2nd line vs. 1st line | 1.692 (1.025–2.795) | 0.040 | 1.766 (1.067–2.923) | 0.027 |